{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"India Tech Report","title":"CrisprBits raises $3 million to scale CRISPR diagnostics, biofuel strain engineering","html":"","width":"100%","height":180,"duration":507,"description":"Team CrisprBits. Image source: company.CrisprBits, a Bengaluru biotech startup, has raised $3 million in a pre-Series A round to scale its CRISPR-based diagnostics and gene-editing platforms, lifting its valuation to $12 million. The company plans to use the money to commercialize its PathCrisp molecular diagnostics line and build an AI-augmented strain engineering platform for industrial biofuels.Listen to the episodeSpotifyYouTubeThe round was led by Spectrum Impact, the family office of Aarti Industries Ltd.’s Chairman and Managing Director Rajendra Gogri, with participation from existing backers including the Vijay Alreja Family Office (VJ Technologies Group) and new investors such as the promoter family of HBL Engineering Ltd. Earlier funding from the founders, VJ Technologies Group and C-CAMP is being deployed to expand manufacturing capacity across human health, food safety and animal health applications.CrisprBits’ investment is happening at a time when CRISPR moves from lab tool to commercial platform in diagnostics, gene therapies and industrial biotech, drawing sustained interest from strategics and financial investors worldwide. Global CRISPR technology revenues are projected to grow at around 11–16 percent annually this decade, with estimates putting the broader CRISPR market in the $5–23 billion range by 2030–2035 as applications in healthcare, agriculture and biomanufacturing scale up.“Our focus has always been on attracting patient capital that shares our goal to ‘rewrite biology and reimagine the planet,’ CrisprBits co-founder and CEO Vijay Chandru, said in a press release. “This round gives us the fuel to launch in India and immediately scale to global markets with high-quality, affordable solutions,” he said.CrisprBits’ PathCrisp platform targets rapid, point-of-need molecular diagnostics, promising sample-to-result times of under 2.5 hours with minimal infrastructure. The product line spans tests for typhoid, antimicrobial resistance, sickle...","thumbnail_url":"https://img.transistorcdn.com/klwtZi6_OVxR1RQx-EUqBBLq9JNmkk2p0xt3ov7-eeg/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kYjRi/MTNkNDVhMTVlOThm/MDM4ZmVlYjFmZGNl/OGFiNy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}